Connect your AI

Rigel Pharmaceuticals RIGL Stock-Based Comp

Stock-Based Comp at other companies

AmgenAMGN

$75M-11.8%

Agios PharmaceuticalsAGIO

$15.54M+36.8%

Nuvation BioNUVB

$9.03M+15.0%

Zevra Therapeutics, Inc.ZVRA

$3.11M-0.3%

Gyre Therapeutics, Inc.GYRE

$2.58M+409%

Eton Pharmaceuticals, Inc.ETON

$1.52M+26.5%

Other financials

Income statement

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Balance sheet

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Cash flow

Operating cash flow$2.7M+405%

CapEx$73.0K—

Free cash flow-$22.0M—

Valuation

Market cap$684.39M+102%

Enterprise value$728.29M+148%

P/E1.9×-7.2×

P/S2.3×+0.6×

Profitability

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

FCF margin-61.7%—

Returns & leverage

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Rigel Pharmaceuticals's stock-based comp?: Rigel Pharmaceuticals (RIGL) reported stock-based comp of $3.46M in Q1 2026.
How has Rigel Pharmaceuticals's stock-based comp changed year-over-year?: Rigel Pharmaceuticals's stock-based comp increased by 4.0% year-over-year, from $3.32M to $3.46M.
What is the long-term trend for Rigel Pharmaceuticals's stock-based comp?: Over 4 years (2021 to 2025), Rigel Pharmaceuticals's stock-based comp has grown at a 7.6% compound annual growth rate (CAGR), from $9.49M to $12.71M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.